Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 359

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 359
---
 reports with staggered compliance dates for large accelerated filers for the various aspects of the Final Rule. On April 4, 2024, the SEC issued an order staying the Final Rule. The SEC’s administrative stay is expected to remain in place until the completion of litigation filed in various federal courts challenging, among other things, the agency’s authority to adopt the Final Rule. The Company is evaluating the final rule to determine its impact on the Company's disclosures. 

3. Disaggregated Revenues

The following table provides information regarding total revenues (dollars in thousands): Year Ended December 31, 202420232022Net product sales   Qelbree$241,273 $140,192 $61,322 GOCOVRI130,824 119,637 104,421 Oxtellar XR99,464 113,404 115,345 APOKYN73,926 75,083 75,305 Trokendi XR63,201 94,336 261,221 Other(1)29,008 31,281 31,818 Total net product sales637,696 573,933 649,432 Royalty, licensing and other revenues24,121 33,588 17,806 Total revenues$661,817 $607,521 $667,238 ______________________________(1)   Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.In December 2023, the Company submitted to the FDA a notification of discontinuance to withdraw Osmolex ER from distribution. Distribution of Osmolex ER ceased on April 1, 2024.The Company recognized noncash royalty revenues of $4.0 million, and $9.8 million for the years ended December 31, 2023 and 2022, respectively. The Company no longer recognizes noncash royalty revenue as ownership of the royalty rights reverted back to the Company during the second quarter of 2023 (see Note 2, Summary of Significant Accounting Policies).Adjustments related to prior year sales in 2024 was less than 3% of net product sales. The majority of the adjustment is attributable to Qelbree, reflecting favorable actual returns experienced in 2024. As a result, the Company changed its estimated provision for product returns based on the most recent experience. In 2023 and 2022, adjustments related to prior year sales have amounted to